A pharmaceutical company contracted Aptuit for an integrated program of radiolabeled synthesis and preclinical testing that included absorption, distribution, metabolic and excretion (ADME) animal studies, and in vivo profiling. Aptuit is one of only a few drug development companies that can offer GLP and cGMP radiolabeled synthesis through its API Development & Manufacture group and ADME services through its Pharmaceutical Development & Manufacture group.

These studies, using radiolabeled compounds, provide essential data when establishing a drug safety profile. Radio synthesis provides a radiolabeled drug that is used to investigate the pharmacokinetics of a new compound in preclinical species. This enables the prediction of the behavior of the new compound in humans. Aptuit's preclinical team paves the way for a novel compound to be developed as a safe and effective treatment and the Aptuit team can optimize drug development programs to ensure IND submission.

Download this free white paper to find out more.